Evidence and patents
- SMi has established proof-of-concept and generated evidence for its use; results and published findings are underpinned by a growing IP portfolio (WO2020245579A1)
- UKCA/CE marking of the instrument achieved in Q2 2023
- Active projects with the University of Cambridge, Medicines Discovery Catapult and National Physical Laboratory
Competitive analysis
Technological comparisons highlight that SMi holds advantages over competitors when considering key metrics relevant to each market segment including: precise counting, richness of data, processing speeds, target multiplexing, panel flexibility and ease of use.
Commercial plan
Contacts
Andrew Thompson, CEO
andrew.thompson@smisystems.co.uk
+44 (0) 7706 336915
James Clark, CFO
james.clark@smisystems.co.uk
+44 (0) 7788 446422
Disclaimer
The content of this communication has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this communication for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.